Parkinson disease psychosis: from phenomenology to neurobiological mechanisms

Diagnostic and Statistical Manual of Mental Disorders

American Psychiatric Association (2022) · doi:10.1176/appi.books.9780890425787 · Cited by 23,476 · see citing works

Control of goal-directed and stimulus-driven attention in the brain

Corbetta, M., & Shulman, G. L. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn755 · Cited by 12,881 · see citing works

The human brain is intrinsically organized into dynamic, anticorrelated functional networks

Fox, M. D., Snyder, A. Z., Vincent, J. L., Corbetta, M., Van Essen, D. C., & Raichle, M. E. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504136102 · Cited by 8,553 · see citing works

Source monitoring.

Johnson, M. K., Hashtroudi, S., & Lindsay, D. S. (1993) · Psychological Bulletin · doi:10.1037/0033-2909.114.1.3 · Cited by 3,392 · see citing works

Spontaneous neuronal activity distinguishes human dorsal and ventral attention systems

Fox, M. D., Corbetta, M., Snyder, A. Z., Vincent, J. L., & Raichle, M. E. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604187103 · Cited by 2,101 · see citing works

Parkinson disease-associated cognitive impairment

Aarsland, D., Batzu, L., Halliday, G. M., Geurtsen, G. J., Ballard, C. G., Chaudhuri, К. R., & Weintraub, D. A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00280-3 · Cited by 1,441 · see citing works

An Introduction to the Endogenous Cannabinoid System

Lu, H.-C., & Mackie, K. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.07.028 · Cited by 1,234 · see citing works

Rivastigmine for Dementia Associated with Parkinson's Disease

Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., Deyn, P. P. D., Durif, F., Kulisevsky, J., van Laar, T., Lees, A. J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041470 · Cited by 1,219 · see citing works

Multisensory brain mechanisms of bodily self-consciousness.

Blanke, O. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3292 · Cited by 1,147 · see citing works

The brain’s default network: updated anatomy, physiology and evolving insights

Buckner, R. L., & DiNicola, L. M. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0212-7 · Cited by 1,058 · see citing works

Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors

Fénelon, G. (2000) · Brain · doi:10.1093/brain/123.4.733 · Cited by 1,035 · see citing works

Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review

Seppi, K., Chaudhuri, К. R., Coelho, M. M., Fox, S. H., Katzenschlager, R., Perez‐Lloret, S., Weintraub, D. A., & Sampaio, C. (2019) · Movement Disorders · doi:10.1002/mds.27602 · Cited by 1,013 · see citing works

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial

Cummings, J. L., Isaacson, S., Mills, R., Williams, H., Chi‐Burris, K., Corbett, A., Dhall, R., & Ballard, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)62106-6 · Cited by 954 · see citing works

A feedforward architecture accounts for rapid categorization

Serre, T., Oliva, A., & Poggio, T. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700622104 · Cited by 918 · see citing works

A cortical mechanism for triggering top-down facilitation in visual object recognition

Bar, M. (2003) · Journal of Cognitive Neuroscience · doi:10.1162/089892903321662976 · Cited by 900 · see citing works

Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease

Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696 · see citing works

Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial

McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., Taylor, A., & Wright, S. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17030325 · Cited by 617 · see citing works

Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease

The Parkinson Study Group (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401003 · Cited by 616 · see citing works

Endocannabinoid signaling as a synaptic circuit breaker in neurological disease

Katona, I., & Freund, T. F. (2008) · Nature Medicine · doi:10.1038/nm.f.1869 · Cited by 579 · see citing works

Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.

Perry, E. K., Curtis, M., Dick, D. J., Candy, J., Atack, J. R., Bloxham, C. A., Blessed, G., FAIRBAIRN, A. F., Tomlinson, B. E., & Perry, R. H. (1985) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.48.5.413 · Cited by 572 · see citing works

Basal forebrain neurons in the dementia of Parkinson disease

Whitehouse, P. J., Hedreen, J. C., White, C. L., & Price, D. L. (1983) · Annals of Neurology · doi:10.1002/ana.410130304 · Cited by 535 · see citing works

Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group

Ravina, B., Marder, K., Fernandez, H. H., Friedman, J. H., McDonald, W., Murphy, D., Aarsland, D., Babcock, D., Cummings, J., Endicott, J., et al. (2007) · Movement Disorders · doi:10.1002/mds.21382 · Cited by 528 · see citing works

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function

Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506 · cited 1× · see citing works

Why people see things that are not there: A novel Perception and Attention Deficit model for recurrent complex visual hallucinations

Collerton, D., Perry, E. K., & McKeith, I. G. (2005) · Behavioral and Brain Sciences · doi:10.1017/s0140525x05000130 · Cited by 437 · see citing works

At the heart of the ventral attention system: The right anterior insula

Eckert, M. A., Menon, V., Walczak, A., Ahlstrom, J., Denslow, S., Horwitz, A., & Dubno, J. R. (2009) · Human Brain Mapping · doi:10.1002/hbm.20688 · Cited by 406 · see citing works

A 12-Year Population-Based Study of Psychosis in Parkinson Disease

Forsaa, E. B., Larsen, J. P., Wentzel‐Larsen, T., Goetz, C. G., Stebbins, G. T., Aarsland, D., & Alves, G. W. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.166 · Cited by 400 · see citing works

Predictors of dementia in Parkinson disease

Anang, J. B. M., Gagnon, J., Bertrand, J., Romenets, S. R., Latreille, V., Panisset, M., Montplaisir, J. Y., & Postuma, R. B. (2014) · Neurology · doi:10.1212/wnl.0000000000000842 · Cited by 379 · see citing works

Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET

Shimada, H., Hirano, S., Shinotoh, H., Aotsuka, A., Sato, K., Tanaka, N., Ota, T., Asahina, M., Fukushi, K., Kuwabara, S., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181ab2b58 · Cited by 367 · see citing works

Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial

Chagas, M. H. N., Zuardi, A. W., Tumas, V., Pena-Pereira, M. A., Sobreira, E. T., Bergamaschi, M. M., dos Santos, A. C., Teixeira, A. L., Hallak, J. E., & Crippa, J. A. S. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114550355 · Cited by 365 · see citing works

A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia

Aarsland, D., Ballard, C. G., Larsen, J. O., & McKeith, I. G. (2001) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.389 · Cited by 357 · see citing works

Cannabidiol for the treatment of psychosis in Parkinson's disease

Zuardi, A., Crippa, J., Hallak, J., Pinto, J., Chagas, M., Rodrigues, G., Dursun, S., & Tumas, V. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108096519 · Cited by 355 · see citing works

The psychosis spectrum in Parkinson disease

ffytche, D. H., Creese, B., Politis, M., Chaudhuri, K. R., Weintraub, D., Ballard, C., & Aarsland, D. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.200 · Cited by 355 · see citing works

Prospective study of hallucinations and delusions in Parkinson's disease

Holroyd, S. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.6.734 · Cited by 346 · see citing works

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

Pollak, P. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.029868 · Cited by 332 · see citing works

Levodopa-induced psychosis: a kindling phenomenon

Moskovitz, C., Moses, H., & Klawans, H. L. (1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.6.669 · Cited by 325 · see citing works

Psychiatric Morbidity in Dementia With Lewy Bodies: A Prospective Clinical and Neuropathological Comparative Study With Alzheimer’s Disease

Ballard, C. G., Holmes, C., McKeith, I. G., Neill, D., O'Brien, J. T., Cairns, N. J., Lantos, P. L., Perry, E. K., Ince, P. G., & Perry, R. H. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.1039 · Cited by 312 · see citing works

Hallucinations in Parkinson disease

Diederich, N. J., Fénelon, G., Stebbins, G., & Goetz, C. G. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.62 · Cited by 312 · see citing works

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease

Burn, D. J., Emre, M., McKeith, I. G., Deyn, P. P. D., Aarsland, D., Hsu, C., & Lane, R. M. (2006) · Movement Disorders · doi:10.1002/mds.21077 · Cited by 310 · see citing works

Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches

Bohnen, N. I., Yarnall, A. J., Weil, R. S., Moro, E., Moehle, M. S., Borghammer, P., Bédard, M., & Albin, R. L. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00377-x · Cited by 309 · see citing works

Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial

Henderson, E. J., Lord, S. R., Brodie, M. A. D., Gaunt, D., Lawrence, A. D., Close, J., Whone, A. L., & Ben‐Shlomo, Y. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00389-0 · Cited by 304 · see citing works

Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study

Williams, D. R., & Lees, A. J. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70146-0 · Cited by 302 · see citing works

A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia

Koblan, K. S., KENT, J. M., Hopkins, S. C., Krystal, J. H., Cheng, H., GOLDMAN, R. S., & Loebel, A. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911772 · Cited by 300 · see citing works

Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis

Meltzer, H. Y., Mills, R., Revell, S., Williams, H., Johnson, A. D., Bahr, D., & Friedman, J. H. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.176 · Cited by 293 · see citing works

Mortality and hallucinations in nursing home patients with advanced Parkinson's disease

Goetz, C. G., & Stebbins, G. T. (1995) · Neurology · doi:10.1212/wnl.45.4.669 · Cited by 291 · see citing works

Ophthalmologic features of Parkinson’s disease

Biousse, V., Skibell, B. C., Watts, R. L., Loupe, D. N., Drews‐Botsch, C., & Newman, N. J. (2004) · Neurology · doi:10.1212/01.wnl.0000103444.45882.d8 · Cited by 286 · see citing works

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial

Reading, P., Luce, A., & McKeith, I. G. (2001) · Movement Disorders · doi:10.1002/mds.1204 · Cited by 269 · see citing works

Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease

Ballanger, B., Strafella, A. P., van Eimeren, T., Zurowski, M., Rusjan, P. M., Houle, S., & Fox, S. H. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.35 · Cited by 266 · see citing works

The 5-HT3 receptor – the relationship between structure and function

Barnes, N. M., Hales, T. G., Lummis, S. C. R., & Peters, J. A. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.003 · Cited by 261 · see citing works

Olanzapine and clozapine

Goetz, C. G., Blasucci, L. M., Leurgans, S. E., & Pappert, E. J. (2000) · Neurology · doi:10.1212/wnl.55.6.789 · Cited by 249 · see citing works

Minor hallucinations occur in drug‐naive Parkinson's disease patients, even from the premotor phase

Pagonabarraga, J., Martinez‐Horta, S., Fernández de Bobadilla, R., Pérez, J., Ribosa‐Nogué, R., Marín, J., Pascual‐Sedano, B., García, C., Gironell, A., & Kulisevsky, J. (2016) · Movement Disorders · doi:10.1002/mds.26432 · Cited by 236 · see citing works

The changing face of Parkinson's disease‐associated psychosis: A cross‐sectional study based on the new NINDS‐NIMH criteria

Fénelon, G., Soulas, T., Zenasni, F., & de Langavant, L. C. (2010) · Movement Disorders · doi:10.1002/mds.22839 · Cited by 218 · see citing works

Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia

Kulisevsky, J., Pagonabarraga, J., Pascual‐Sedano, B., García‐Sánchez, C., Gironell, A., & Trapecio Group Study (2008) · Movement Disorders · doi:10.1002/mds.22246 · Cited by 216 · see citing works

Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2 R,3 R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist

Vanover, K. E., Weiner, D. M., Makhay, M. M., Veinbergs, I., Gardell, L. R., Lameh, J., Tredici, A. L. D., Piu, F., Schiffer, H. H., Ott, T. R., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.097006 · Cited by 206 · see citing works

Visual misperceptions and hallucinations in Parkinson's disease: Dysfunction of attentional control networks?

Shine, J. M., Halliday, G. M., Naismith, S. L., & Lewis, S. J. G. (2011) · Movement Disorders · doi:10.1002/mds.23896 · Cited by 205 · see citing works

Parkinson's disease: drug-induced psychiatric states.

Factor, S. A., Molho, E., Podskalny, G. D., & Brown, D. L. (1995) · PubMed · Cited by 203 · see citing works

Psychosis in advanced Parkinson's disease

Zoldan, J., Friedberg, G., Livneh, M., & Melamed, E. (1995) · Neurology · doi:10.1212/wnl.45.7.1305 · Cited by 192 · see citing works

Reality monitoring and visual hallucinations in Parkinson’s disease

Barnes, J., Boubert, L., Harris, J., Lee, A., & David, A. S. (2003) · Neuropsychologia · doi:10.1016/s0028-3932(02)00182-3 · Cited by 192 · see citing works

Altered cortical visual processing in PD with hallucinations

Stebbins, G. T., Goetz, C. G., Carrillo, M. C., Bangen, K. J., Turner, D. A., Glover, G. H., & Gabrieli, J. D. E. (2004) · Neurology · doi:10.1212/01.wnl.0000141853.27081.bd · Cited by 189 · see citing works

Characteristics of Visual Hallucinations in Parkinson Disease Dementia and Dementia With Lewy Bodies

Mosimann, U. P., Rowan, E. N., Partington, C. E., Collerton, D., Littlewood, E., O'Brien, J. T., Burn, D. J., & McKeith, I. G. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000192480.89813.80 · Cited by 188 · see citing works

Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations

Meppelink, A. M., de Jong, B. M., Renken, R. J., Leenders, K. L., Cornelissen, F. W., & van Laar, T. (2009) · Brain · doi:10.1093/brain/awp223 · Cited by 183 · see citing works

Prospective longitudinal assessment of hallucinations in Parkinson’s disease

Goetz, C. G., Leurgans, S. E., Pappert, E. J., Raman, R., & Stemer, A. B. (2001) · Neurology · doi:10.1212/wnl.57.11.2078 · Cited by 179 · see citing works

Hallucinations in Parkinson disease in the prelevodopa era

Fénelon, G., Goetz, C. G., & Karenberg, A. (2006) · Neurology · doi:10.1212/01.wnl.0000191325.31068.c4 · Cited by 171 · see citing works

Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease

Weintraub, D. A., Chiang, C., Kim, H. M., Wilkinson, J. R., Marras, C., Stanislawski, B., Mamikonyan, E., & Kales, H. C. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0031 · Cited by 169 · see citing works

The Malignant Course of “Benign Hallucinations” in Parkinson Disease

Goetz, C. G., Fan, W., Leurgans, S. E., Bernard, B. A., & Stebbins, G. T. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.713 · Cited by 161 · see citing works

Early dopaminergic drug-induced hallucinations in parkinsonian patients

Goetz, C. G., Vogel, C., Tanner, C. M., & Stebbins, G. T. (1998) · Neurology · doi:10.1212/wnl.51.3.811 · Cited by 156 · see citing works

Cerebral atrophy in Parkinson's disease patients with visual hallucinations

Ramírez‐Ruiz, B., Martí, M., TOLOSA, E. S., Giménez, M., Bargalló, N., Valldeoriola, F., & Junqué, C. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.01768.x · Cited by 154 · see citing works

Increased 5‐HT_2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations

Huot, P., Johnston, T. H., Darr, T., Hazrati, L., Visanji, N. P., Pires, D., Brotchie, J. M., & Fox, S. H. (2010) · Movement Disorders · doi:10.1002/mds.23083 · Cited by 153 · see citing works

Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson’s disease with hallucinations

Goldman, J. G., Stebbins, G. T., Dinh, V., Bernard, B. A., Merkitch, D., deToledo‐Morrell, L., & Goetz, C. G. (2014) · Brain · doi:10.1093/brain/awt360 · Cited by 152 · see citing works

The default mode network is disrupted in parkinson's disease with visual hallucinations

Yao, N., Chang, R. S., Cheung, C., Pang, S. Y.-Y., Lau, K. K., John Suckling, A., Rowe, J. B., Yu, K., Mak, H. K., Chua, S.-E., et al. (2014) · Human Brain Mapping · doi:10.1002/hbm.22577 · Cited by 151 · see citing works

Trial of pimavanserin in dementia-related psychosis

Tariot, P. N., Cummings, J. L., Soto-Martin, M. E., Ballard, C., Erten-Lyons, D., Sultzer, D. L., Devanand, D. P., Weintraub, D., McEvoy, B., Youakim, J. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034634 · Cited by 145 · cited 1× · see citing works

Neural correlates of psychotic symptoms in dementia with Lewy bodies.

Nagahama, Y., Okina, T., Suzuki, N., & Matsuda, M. (2010) · Brain : a journal of neurology · doi:10.1093/brain/awp295 · Cited by 140 · see citing works

Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations

Oishi, N., Udaka, F., Kameyama, M., Sawamoto, N., Hashikawa, K., & Fukuyama, H. (2005) · Neurology · doi:10.1212/01.wnl.0000187116.13370.e0 · Cited by 137 · see citing works

Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects

Marco, E. M. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00063 · Cited by 136 · see citing works

Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management

O'Brien, J. T., Taylor, J., Ballard, C. G., Barker, R. A., Bradley, C., Burns, A. S., Collerton, D., Dave, S., Dudley, R. E. J., Francis, P. T., et al. (2020) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322702 · Cited by 136 · see citing works

Hippocampal head atrophy predominance in Parkinson’s disease with hallucinations and with dementia

Ibarretxe‐Bilbao, N., Ramírez‐Ruiz, B., Tolosa, E., Martı́, M. J., Valldeoriola, F., Bargalló, N., & Junqué, C. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0885-8 · Cited by 134 · see citing works

The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease

Shine, J. M., Halliday, G. M., Gilat, M., Matar, E., Bolitho, S., Carlos, M., Naismith, S. L., & Lewis, S. J. G. (2013) · Human Brain Mapping · doi:10.1002/hbm.22321 · Cited by 133 · see citing works

Differential progression of brain atrophy in Parkinson's disease with and without visual hallucinations

Ibarretxe‐Bilbao, N., Ramírez‐Ruiz, B., Junqué, C., Martí, M. J., Valldeoriola, F., Bargalló, N., Juanes, S., & Tolosa, E. (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.179655 · Cited by 133 · see citing works

Pharmacology of hallucinations induced by long-term drug therapy

Goetz, C. G., Tanner, C. M., & Klawans, H. L. (1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.4.494 · Cited by 129 · see citing works

Risperidone for hallucinations in levodopa-treated Parkinson's disease patients

Meco, G., Alessandria, A., Bonifati, V., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92511-9 · Cited by 128 · see citing works

Frontal and associative visual areas related to visual hallucinations in dementia with Lewy bodies and Parkinson's disease with dementia

Sánchez‐Castañeda, C., Reñé, R., Ramírez‐Ruiz, B., Campdelacreu, J., Gascón, J., Falcón, C., Calopa, M., Jaumà, S., Juncadella, M., & Junqué, C. (2010) · Movement Disorders · doi:10.1002/mds.22873 · Cited by 126 · see citing works

Feeling of presence in Parkinson's disease

Fénelon, G., Soulas, T., de Langavant, L. C., Trinkler, I., & Bachoud‐Lévi, A. (2011) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.234799 · Cited by 126 · see citing works

The therapeutic potential of cannabinoids for movement disorders

Kluger, B. M., Triolo, P. M., Jones, W. E., & Jankovic, J. J. (2015) · Movement Disorders · doi:10.1002/mds.26142 · Cited by 123 · see citing works

Course of psychiatric symptoms and global cognition in early Parkinson disease

de la Riva, P., Smith, K. M., Xie, S. X., & Weintraub, D. A. (2014) · Neurology · doi:10.1212/wnl.0000000000000801 · Cited by 123 · see citing works

Metabolic Alterations in Patients With Parkinson Disease and Visual Hallucinations

Boecker, H., Ceballos-Baumann, A., Volk, D., Conrad, B., Förstl, H., & Häussermann, P. (2007) · Archives of Neurology · doi:10.1001/archneur.64.7.984 · Cited by 123 · see citing works

Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease

Manganelli, F., Vitale, C., Santangelo, G., Pisciotta, C., Iodice, R., Cozzolino, A., Dubbioso, R., Picillo, M., Barone, P., & Santoro, L. (2009) · Brain · doi:10.1093/brain/awp166 · Cited by 122 · see citing works

Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo

Laere, K. V., Casteels, C., Lunskens, S., Goffin, K. E., Grachev, I. D., Bormans, G. M., & Vandenberghe, W. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.009 · Cited by 120 · see citing works

The pedunculopontine nucleus is related to visual hallucinations in Parkinson’s disease: preliminary results of a voxel-based morphometry study

Janzen, J., Ent, D. V. ‘., Lemstra, A. W., Berendse, H. W., Barkhof, F., & Foncke, E. M. J. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6149-z · Cited by 120 · see citing works

Abnormal brain glucose metabolism in the delusional misidentification syndromes: A positron emission tomography study in Alzheimer disease

Mentis, M. J., Weinstein, E. A., Horwitz, B., McIntosh, A. R., Pietrini, P., Alexander, G. E., Furey, M., & Murphy, D. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00326-x · Cited by 119 · see citing works

Hallucinations in Parkinson's disease: A follow‐up study

de Maindreville, A. D., Fénelon, G., & Mahieux, F. (2004) · Movement Disorders · doi:10.1002/mds.20263 · Cited by 119 · see citing works

Frequency, prevalence, incidence and risk factors associated with visual hallucinations in a sample of patients with Parkinson's disease: a longitudinal 4‐year study

Gibson, G., Mottram, P. G., Burn, D. J., Hindle, J. V., Landau, S., Samuel, M., Hurt, C. S., Brown, R. G., & Wilson, K. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3869 · Cited by 117 · see citing works

Minor hallucinations in Parkinson disease

Lenka, A., Pagonabarraga, J., Pal, P. K., Bejr‐Kasem, H., & Kulisvesky, J. (2019) · Neurology · doi:10.1212/wnl.0000000000007913 · Cited by 113 · see citing works

Neuropsychological deficits in Parkinson's disease patients with visual hallucinations

Ramírez‐Ruiz, B., Junqué, C., Martı́, M. J., Valldeoriola, F., & TOLOSA, E. S. (2006) · Movement Disorders · doi:10.1002/mds.20965 · Cited by 112 · see citing works

Visual Predictions in the Orbitofrontal Cortex Rely on Associative Content

Chaumon, M., Kveraga, K., Barrett, L. F., & Bar, M. (2013) · Cerebral Cortex · doi:10.1093/cercor/bht146 · Cited by 109 · see citing works

Abnormal connectivity between the default mode and the visual system underlies the manifestation of visual hallucinations in Parkinson’s disease: a task-based fMRI study

Shine, J. M., Muller, A. J., O’Callaghan, C., Hornberger, M., Halliday, G. M., & Lewis, S. J. (2015) · npj Parkinson's Disease · doi:10.1038/npjparkd.2015.3 · Cited by 106 · see citing works

Visual hallucination in Parkinson's disease with FDG PET

Nagano‐Saito, A., Washimi, Y., Arahata, Y., Iwai, K., Kawatsu, S., Ito, K., Nakamura, A., Abe, Y., Yamada, T., Kato, T., et al. (2004) · Movement Disorders · doi:10.1002/mds.20129 · Cited by 105 · see citing works

Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: A double-blind, randomized, placebo-controlled study

Zhang, Z., Kang, W.-H., Li, Q., et al. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.07.010 · Cited by 104 · see citing works

Mesolimbic Dopamine Function Is Related to Salience Network Connectivity: An Integrative Positron Emission Tomography and Magnetic Resonance Study

McCutcheon, R. A., Nour, M. M., Dahoun, T., Jauhar, S., Pepper, F., Expert, P., Veronese, M., Adams, R. A., Turkheimer, F., Mehta, M. A., et al. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.09.010 · Cited by 104 · see citing works

Neural correlates of minor hallucinations in non-demented patients with Parkinson's disease

Pagonabarraga, J., Soriano‐Mas, C., Llebaria, G., López‐Solà, M., Pujol, J., & Kulisevsky, J. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.11.017 · Cited by 103 · see citing works

Tactile hallucinations in Parkinson's disease

F�nelon, G., Thobois, S., Bonnet, A.-M., Broussolle, E., & Tison, F. (2002) · Journal of Neurology · doi:10.1007/s00415-002-0908-9 · Cited by 98 · see citing works

Imagine that: elevated sensory strength of mental imagery in individuals with Parkinson's disease and visual hallucinations

Shine, J. M., Keogh, R., O'Callaghan, C., Muller, A. J., Lewis, S. J. G., & Pearson, J. (2015) · Proceedings of the Royal Society B: Biological Sciences · doi:10.1098/rspb.2014.2047 · Cited by 97 · see citing works

Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases

Cheng, A. V., Ferrier, I. N., Morris, C. M., Jabeen, S., Sahgal, A., McKeith, I. G., Edwardson, J. A., Perry, R. H., & Perry, E. K. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90193-b · Cited by 96 · see citing works

Classification of psychotic symptoms in dementia with Lewy bodies.

Nagahama, Y., Okina, T., Suzuki, N., Matsuda, M., Fukao, K., & Murai, T. (2007) · The American journal of geriatric psychiatry · doi:10.1097/jgp.0b013e3180cc1fdf · Cited by 93 · see citing works

Cortical and subcortical brain atrophy in Parkinson's disease with visual hallucination

Watanabe, H., Senda, J., Kato, S., Ito, M., Atsuta, N., Hara, K., Tsuboi, T., Katsuno, M., Nakamura, T., Hirayama, M., et al. (2013) · Movement Disorders · doi:10.1002/mds.25641 · Cited by 92 · see citing works

Ondansetron for hallucinosis in advanced Parkinson's disease

Zoldan, J., Friedberg, G., Goldberg‐Stern, H., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)90327-d · Cited by 91 · see citing works

Visual plus nonvisual hallucinations in Parkinson's disease: Development and evolution over 10 years

Goetz, C. G., Stebbins, G. T., & Ouyang, B. (2011) · Movement Disorders · doi:10.1002/mds.23835 · Cited by 91 · see citing works

Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders

Halff, E. F., Rutigliano, G., Garcia-Hidalgo, A., & Howes, O. D. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.10.010 · Cited by 90 · see citing works

Brain response to complex visual stimuli in Parkinson's patients with hallucinations: A functional magnetic resonance imaging study

Ramírez‐Ruiz, B., Martı́, M. J., TOLOSA, E. S., Falcón, C., Bargalló, N., Valldeoriola, F., & Junqué, C. (2008) · Movement Disorders · doi:10.1002/mds.22258 · Cited by 89 · see citing works

Object knowledge during entry-level categorization is activated and modified by implicit memory after 200 ms

Schendan, H. E., & Maher, S. M. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.09.061 · Cited by 88 · see citing works

Visual hallucinations in Parkinson's disease: Theoretical models

Muller, A. J., Shine, J. M., Halliday, G. M., & Lewis, S. J. G. (2014) · Movement Disorders · doi:10.1002/mds.26004 · Cited by 85 · see citing works

Auditory and visual hallucination prevalence in Parkinson's disease and dementia with Lewy bodies: a systematic review and meta-analysis

Eversfield, C. L., & Orton, L. D. (2018) · Psychological Medicine · doi:10.1017/s0033291718003161 · Cited by 85 · see citing works

The delusional misidentification syndromes: Strange, fascinating, and instructive

Christodoulou, G. N., Margariti, M. M., Kontaxakis, V. P., & Christodoulou, N. G. (2009) · Current Psychiatry Reports · doi:10.1007/s11920-009-0029-6 · Cited by 83 · see citing works

Neuroanatomical substrates of visual hallucinations in patients with non-demented Parkinson's disease

Shin, S., Lee, J. E., Hong, J. Y., Sunwoo, M.-K., Sohn, Y. H., & Lee, P. H. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303391 · Cited by 83 · see citing works

Understanding visual hallucinations: A new synthesis

Collerton, D., Barnes, J., Diederich, N. J., Dudley, R., ffytche, D., Friston, K., Goetz, C. G., Goldman, J. G., Jardri, R., Kulisevsky, J., et al. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105208 · Cited by 83 · see citing works

Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience

Balash, Y., Schleider, L. B., Korczyn, A. D., Shabtai, H., Knaani, J., Rosenberg, A., Baruch, Y., Djaldetti, R., Giladi, N., & Gurevich, T. (2017) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000246 · Cited by 82 · see citing works

Default mode network links to visual hallucinations: A comparison between Parkinson's disease and multiple system atrophy

Franciotti, R., Pizzi, S. D., Perfetti, B., Tartaro, A., Bonanni, L., Thomas, A., Weis, L., Biundo, R., Antonini, A., & ONOFRJ, M. C. (2015) · Movement Disorders · doi:10.1002/mds.26285 · Cited by 79 · see citing works

Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease

Llebaria, G., Pagonabarraga, J., Martínez‐Corral, M., García‐Sánchez, C., Pascual‐Sedano, B., Gironell, A., & Kulisevsky, J. (2010) · Movement Disorders · doi:10.1002/mds.23411 · Cited by 79 · see citing works

Hallucinations, somatic‐functional disorders of PD‐DLB as expressions of thalamic dysfunction

ONOFRJ, M. C., Espay, A. J., Bonanni, L., Pizzi, S. D., & Sensi, S. L. (2019) · Movement Disorders · doi:10.1002/mds.27781 · Cited by 79 · see citing works

Endocannabinoid system in psychotic and mood disorders, a review of human studies

Ramesh, R. G., Watts, J. J., & Mizrahi, R. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110096 · Cited by 79 · see citing works

Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment.

Wolters, E. C. (1999) · PubMed · Cited by 78 · see citing works

Bromocriptine treatment in Parkinson's disease.

Parkes, J. D., MARSDEN, C. D., Donaldson, I. M., et al. (1976) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.39.2.184 · Cited by 76 · see citing works

Disruption of the default mode network and its intrinsic functional connectivity underlies minor hallucinations in Parkinson's disease

Bejr‐Kasem, H., Pagonabarraga, J., Martínez‐Horta, S., Sampedro, F., Marín‐Lahoz, J., Horta‐Barba, A., Aracil‐Bolaños, I., Pérez‐Pérez, J., Boti, M. A., Campolongo, A., et al. (2018) · Movement Disorders · doi:10.1002/mds.27557 · Cited by 76 · see citing works

Psychiatric aspects in Parkinsonism treated with L-dopa

Damásio, A. R., Lobo-Antunes, J., & Macedo, C. (1971) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.34.5.502 · Cited by 75 · see citing works

Hypoperfusion of the visual pathway in parkinsonian patients with visual hallucinations

Matsui, H., Nishinaka, K., Oda, M., Hara, N., Komatsu, K., Kubori, T., & Udaka, F. (2006) · Movement Disorders · doi:10.1002/mds.21140 · Cited by 73 · see citing works

Altered Cholinergic Innervation in De Novo Parkinson's Disease with and Without Cognitive Impairment

van der Zee, S., Kanel, P., Gerritsen, M. J. J., Boertien, J. M., Slomp, A. C., Müller, M. L. T. M., Bohnen, N. I., Spikman, J. M., & van Laar, T. (2022) · Movement Disorders · doi:10.1002/mds.28913 · Cited by 72 · see citing works

Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis

d’Angremont, E., Begemann, M. J. H., van Laar, T., & Sommer, I. E. C. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.1835 · Cited by 71 · see citing works

Post‐Synaptic 5‐HT1A and 5‐HT2A Receptors Are Increased in Parkinson's Disease Neocortex

Chen, C., ALDER, J. T., Bray, L., et al. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb10229.x · Cited by 69 · see citing works

Resting activity in visual and corticostriatal pathways in Parkinson's disease with hallucinations

Yao, N., Pang, S. Y.-Y., Cheung, C., Chang, R. S., Lau, K. K., Suckling, J., Yu, K., Mak, H. K., McAlonan, G. M., Ho, S., et al. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.11.020 · Cited by 69 · see citing works

Delusional Misidentification in Association With Parkinsonism

Roane, D. M., Rogers, J., Robinson, J., et al. (1998) · Journal of Neuropsychiatry · doi:10.1176/jnp.10.2.194 · Cited by 68 · see citing works

Cognitive correlates of hallucinations and delusions in Parkinson's disease

Factor, S. A., Scullin, M. K., Sollinger, A. B., Land, J. O., Wood‐Siverio, C., Zanders, L., Freeman, A., Bliwise, D. L., McDonald, W. M., & Goldstein, F. C. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.10.033 · Cited by 67 · see citing works

Fiber-specific white matter reductions in Parkinson hallucinations and visual dysfunction

Zarkali, A., McColgan, P., Leyland, L.-A., Lees, A., Rees, G., & Weil, R. (2020) · Neurology · doi:10.1212/wnl.0000000000009014 · Cited by 67 · see citing works

The effects of 5-HT3 receptor antagonists on cognitive performance in aged monkeys

Arnsten, A. F. T., Lin, C. H., van Dyck, C. H., & Stanhope, K. J. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(96)00162-5 · Cited by 66 · see citing works

Increased weighting on prior knowledge in Lewy body-associated visual hallucinations

Zarkali, A., Adams, R. A., Psarras, S., Leyland, L., Rees, G. E., & Weil, R. S. (2019) · Brain Communications · doi:10.1093/braincomms/fcz007 · Cited by 65 · see citing works

I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging

Goetz, C. G., Vaughan, C. L., Goldman, J. G., & Stebbins, G. T. (2013) · Movement Disorders · doi:10.1002/mds.25554 · Cited by 64 · see citing works

Medication-induced hallucination and cerebral blood flow in Parkinson's disease

Okada, K., D, N. S. M., Kobayashi, S., Oguro, H., & Yamaguchi, S. (1999) · Journal of Neurology · doi:10.1007/s004150050364 · Cited by 64 · see citing works

Tropisetron improves deficient inhibitory auditory processing in DBA/2 mice: role of α7 nicotinic acetylcholine receptors

Hashimoto, K., Iyo, M., Freedman, R., & Stevens, K. E. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0142-0 · Cited by 63 · see citing works

Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson disease

Barrett, M. J., Blair, J. C., Sperling, S. A., Smolkin, M. E., & Druzgal, T. J. (2018) · Neurology · doi:10.1212/wnl.0000000000005421 · Cited by 63 · see citing works

Multimodal MRI of the hippocampus in Parkinson’s disease with visual hallucinations

Yao, N., Cheung, C., Pang, S. Y.-Y., Chang, R. S., Lau, K. K., John Suckling, A., Yu, K., Mak, H. K., Chua, S. E., Ho, S., et al. (2014) · Brain Structure and Function · doi:10.1007/s00429-014-0907-5 · Cited by 62 · see citing works

Dopamine agonists and delusional jealousy in Parkinson's disease: A cross‐sectional prevalence study

Poletti, M., Perugi, G., Logi, C., Romano, A., Dotto, P. D., Ceravolo, R., Rossi, G., Pepe, P., Dell’Osso, L., & Bonuccelli, U. (2012) · Movement Disorders · doi:10.1002/mds.25129 · Cited by 57 · see citing works

The neural correlates of hierarchical predictions for perceptual decisions

Weilnhammer, V. A., Stuke, H., Sterzer, P., & Schmack, K. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.2901-17.2018 · Cited by 57 · see citing works

Differences in network controllability and regional gene expression underlie hallucinations in Parkinson’s disease

Zarkali, A., McColgan, P., Ryten, M., Reynolds, R. H., Leyland, L., Lees, A. J., Rees, G. E., & Weil, R. S. (2020) · Brain · doi:10.1093/brain/awaa270 · Cited by 57 · see citing works

The Pharmacology of Visual Hallucinations in Synucleinopathies

Russo, M., Carrarini, C., Dono, F., Rispoli, M. G., Pietro, M. D., Stefano, V. D., Ferri, L., Bonanni, L., Sensi, S. L., & ONOFRJ, M. C. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01379 · Cited by 56 · see citing works

Non-motor symptoms in a prevalent population with Parkinson's disease in Tanzania

Dotchin, C. L., Jusabani, A., & Walker, R. W. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.11.013 · Cited by 55 · see citing works

Minor hallucinations reflect early gray matter loss and predict subjective cognitive decline in Parkinson's disease

Bejr‐Kasem, H., Sampedro, F., Marín‐Lahoz, J., Martínez‐Horta, S., Pagonabarraga, J., & Kulisevsky, J. (2020) · European Journal of Neurology · doi:10.1111/ene.14576 · Cited by 55 · see citing works

Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson's disease patients with mild cognitive impairment

Gasca‐Salas, C., Clavero, P., García‐García, D., Obeso, J. A., & Rodríguez‐Oroz, M. (2015) · Human Brain Mapping · doi:10.1002/hbm.23080 · Cited by 54 · see citing works

Investigating visual misperceptions in Parkinson's disease: A novel behavioral paradigm

Shine, J. M., Halliday, G. M., Carlos, M., Naismith, S. L., & Lewis, S. J. G. (2012) · Movement Disorders · doi:10.1002/mds.24900 · Cited by 53 · see citing works

Mild cognitive impairment in Parkinson’s disease

Martínez‐Horta, S., & Kulisevsky, J. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02003-1 · Cited by 53 · see citing works

Loss of Functional Connectivity in Patients with Parkinson Disease and Visual Hallucinations

Hepp, D. H., Foncke, E. M. J., Dubbelink, K. T. E. O., van de Berg, W. D. J., Berendse, H. W., & Schoonheim, M. M. (2017) · Radiology · doi:10.1148/radiol.2017170438 · Cited by 53 · see citing works

Robot-induced hallucinations in Parkinson’s disease depend on altered sensorimotor processing in fronto-temporal network

Bernasconi, F., Blondiaux, E., Potheegadoo, J., Stripeikyte, G., Pagonabarraga, J., Bejr‐Kasem, H., Bassolino, M., Akselrod, M., Martínez‐Horta, S., Sampedro, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc8362 · Cited by 50 · see citing works

Deconstructing psychosis and misperception symptoms in Parkinson’s disease

Nishio, Y., Yokoi, K., Uchiyama, M., Mamiya, Y., Watanabe, H., Gang, M., Baba, T., Takeda, A., Hirayama, K., & Mori, E. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-315741 · Cited by 47 · see citing works

A prospective study of delusional misidentification syndromes in Parkinson's disease with dementia

Pagonabarraga, J., Llebaria, G., García‐Sánchez, C., Pascual‐Sedano, B., Gironell, A., & Kulisevsky, J. (2007) · Movement Disorders · doi:10.1002/mds.21864 · Cited by 46 · see citing works

Damaged fiber tracts of the nucleus basalis of Meynert in Parkinson’s disease patients with visual hallucinations

Hepp, D. H., Foncke, E. M. J., Berendse, H. W., Wassenaar, T. M., Dubbelink, K. T. E. O., Groenewegen, H. J., van de Berg, W. D. J., & Schoonheim, M. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-10146-y · Cited by 45 · see citing works

Psychotomimetic drugs; chemical and pharmacological aspects.

Hofmann, A. A. (1959) · PubMed · Cited by 44 · see citing works

Hippocampal subfield atrophy in patients with Parkinson’s disease and psychosis

Lenka, A., Ingalhalikar, M., Shah, A., Saini, J. S., Arumugham, S. S., Hegde, S., George, L., Reddy, V., Reddy, Y. C. J., Yadav, R., et al. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1891-3 · Cited by 44 · see citing works

Defining visual illusions in Parkinson's disease: Kinetopsia and object misidentification illusions

Nishio, Y., Yokoi, K., Hirayama, K., Ishioka, T., Hosokai, Y., Gang, M., Uchiyama, M., Baba, T., Suzuki, K., Takeda, A., et al. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.05.023 · Cited by 44 · see citing works

Fifty Percent Prevalence of Extracampine Hallucinations in Parkinson’s Disease Patients

Wood, R. A., Hopkins, S. A., Moodley, K. K., & Chan, D. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00263 · Cited by 42 · see citing works

Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson’s disease and dementia with Lewy bodies: Voxel-based morphometry and neuropsychological meta-analysis

Pezzoli, S., Sánchez‐Valle, R., Solanes, A., Kempton, M. J., Bandmann, O., Shin, J. I., Cagnin, A., Goldman, J. G., Merkitch, D., Firbank, M., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.06.030 · Cited by 42 · see citing works

Mapping brain structural differences and neuroreceptor correlates in Parkinson’s disease visual hallucinations

Vignando, M., ffytche, D., Lewis, S. J. G., Lee, P. H., Chung, S. J., Weil, R. S., Hu, M. T., Mackay, C. E., Griffanti, L., Pins, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28087-0 · Cited by 42 · see citing works

Selective Serotonin 3 Receptor Antagonist Treatment for Schizophrenia: Meta-analysis and Systematic Review

Kishi, T., Mukai, T., Matsuda, Y., & Iwata, N. (2013) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8251-0 · Cited by 41 · see citing works

Altered functional connectivity in lesional peduncular hallucinosis with REM sleep behavior disorder

Geddes, M. R., Tie, Y., Gabrieli, J. D. E., McGinnis, S. M., Golby, A. J., & Whitfield, S. (2015) · Cortex · doi:10.1016/j.cortex.2015.10.015 · Cited by 41 · see citing works

New approaches to understanding hallucinations in Parkinson’s disease: phenomenology and possible origins

Onofrj, M., Thomas, A., & Bonanni, L. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.12.1731 · Cited by 41 · see citing works

Mind-wandering in Parkinson's disease hallucinations reflects primary visual and default network coupling

Walpola, I. C., Muller, A. J., Hall, J. M., Andrews‐Hanna, J. R., Irish, M., Lewis, S. J. G., Shine, J. M., & O’Callaghan, C. (2020) · Cortex · doi:10.1016/j.cortex.2019.12.023 · Cited by 41 · see citing works

Visual loss in Alzheimer’s disease

Duffy, C. J. (1999) · Neurology · doi:10.1212/wnl.52.1.10 · Cited by 40 · see citing works

Lateral geniculate atrophy in Parkinson's with visual hallucination: A trans‐synaptic degeneration?

Lee, J., Yoon, E. J., Lee, W. W., Kim, Y. K., Lee, J., & Jeon, B. (2016) · Movement Disorders · doi:10.1002/mds.26533 · Cited by 40 · see citing works

Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis

Ballard, C. G., Kreitzman, D. L., Isaacson, S., Liu, I.-Y., Norton, J. C., Demos, G., Fernandez, H. H., Ilic, T. V., Azulay, J., Ferreira, J. J., et al. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.06.026 · Cited by 40 · see citing works

Cannabidiol (CBD) as a novel treatment in the early phases of psychosis

Chesney, E., Oliver, D., & McGuire, P. (2022) · Psychopharmacology · doi:10.1007/s00213-021-05905-9 · Cited by 40 · see citing works

Structural brain abnormalities in patients with Parkinson’s disease with visual hallucinations: A comparative voxel-based analysis

Gama, R. L., de Bruin, V. M. S., Távora, D. G. F., Duran, F., Bittencourt, L., & Tufik, S. B. (2014) · Brain and Cognition · doi:10.1016/j.bandc.2014.03.011 · Cited by 39 · see citing works

Relationship between age and subtypes of psychotic symptoms in Parkinson's disease

Kızıltan, G., Özekmekçi, S., Ertan, S., et al. (2007) · Journal of Neurology · doi:10.1007/s00415-006-0388-4 · Cited by 39 · see citing works

Changes in both top-down and bottom-up effective connectivity drive visual hallucinations in Parkinson’s disease

Thomas, G. E. C., Zeidman, P., Sultana, T., Zarkali, A., Razi, A., & Weil, R. S. (2022) · Brain Communications · doi:10.1093/braincomms/fcac329 · Cited by 38 · see citing works

Progression of regional cortical cholinergic denervation in Parkinson’s disease

Bohnen, N. I., Roytman, S., Kanel, P., Müller, M. L. T. M., Scott, P. J. H., Frey, K. A., Albin, R. L., & Koeppe, R. A. (2022) · Brain Communications · doi:10.1093/braincomms/fcac320 · Cited by 37 · see citing works

Top-down modulation of visual processing and knowledge after 250 ms supports object constancy of category decisions

Schendan, H. E., & Ganis, G. (2015) · Frontiers in Psychology · doi:10.3389/fpsyg.2015.01289 · Cited by 35 · see citing works

Cognitive correlates of visual hallucinations in dementia associated with Parkinson's disease

Brønnick, K., Emre, M., Tekin, S., Haugen, S. B., & Aarsland, D. (2011) · Movement Disorders · doi:10.1002/mds.23525 · Cited by 35 · see citing works

Changes in dynamic transitions between integrated and segregated states underlie visual hallucinations in Parkinson’s disease

Zarkali, A., Luppi, A. I., Stamatakis, E. A., Reeves, S., McColgan, P., Leyland, L., Lees, A. J., & Weil, R. S. (2022) · Communications Biology · doi:10.1038/s42003-022-03903-x · Cited by 35 · see citing works

Delusional misidentification syndrome and other unusual delusions in advanced Parkinson's disease

Moro, A., Munhoz, R. P., Moscovich, M., Arruda, W. O., & Teive, H. A. G. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.04.021 · Cited by 34 · see citing works

Selective 5HT3 antagonists and sensory processing: a systematic review

Tsitsipa, E., Rogers, J. P., Casalotti, S., Belessiotis‐Richards, C., Zubko, O., Weil, R. S., Howard, R. J., Bisby, J. A., & Reeves, S. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-021-01255-4 · Cited by 34 · see citing works

Delusions in Parkinson’s Disease: A Systematic Review of Published Cases

Warren, N., O’Gorman, C., Hume, Z., Kisely, S. R., & Siskind, D. J. (2018) · Neuropsychology Review · doi:10.1007/s11065-018-9379-3 · Cited by 32 · see citing works

Longitudinal thalamic white and grey matter changes associated with visual hallucinations in Parkinson’s disease

Zarkali, A., McColgan, P., Leyland, L. A., Lees, A. J., & Weil, R. S. (2022) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-326630 · Cited by 32 · see citing works

Incidence, Prevalence, and Mortality of Psychosis Associated with Parkinson’s Disease (1991–2010)

Stang, C. D., Mullan, A. F., Camerucci, E., Hajeb, M., Turcano, P., Martin, P. R., Mielke, M. M., Josephs, K. A., Splett, M., Abler, V., et al. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-213035 · Cited by 30 · see citing works

Isolated delusional syndrome in Parkinson’s Disease

Stefanis, N. C., Bozi, M., Christodoulou, C., Douzenis, A., Gasparinatos, G., Stamboulis, E., Stefanis, C. N., & Stefanis, L. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.06.010 · Cited by 29 · see citing works

What can we learn from fMRI capture of visual hallucinations in Parkinson’s disease?

Dujardin, K., Roman, D., Baille, G., Pins, D., Lefebvre, S., Delmaire, C., Defebvre, L., & Jardri, R. (2019) · Brain Imaging and Behavior · doi:10.1007/s11682-019-00185-6 · Cited by 29 · see citing works

Relevance of 5-HT2A Receptor Modulation of Pyramidal Cell Excitability for Dementia-Related Psychosis: Implications for Pharmacotherapy

Burstein, E. S. (2021) · CNS Drugs · doi:10.1007/s40263-021-00836-7 · Cited by 29 · see citing works

Clinical and Structural Differences in Delusions Across Diagnoses: A Systematic Review

Rootes-Murdy, K., Goldsmith, D. R., & Turner, J. A. (2022) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2021.726321 · Cited by 29 · see citing works

Paraneoplastic choreic syndrome during non-Hodgkin's lymphoma

Nuti, A., Ceravolo, R., Salvetti, S., Gambaccini, G., Bonuccelli, U., & Capochiani, E. (2000) · Movement Disorders · doi:10.1002/1531-8257(200003)15:2 · Cited by 27 · see citing works

Misidentification Delusions

Perini, G., Carlini, A., Pomati, S., Alberoni, M., Mariani, C. B., Nemni, R., & Farina, E. (2016) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000141 · Cited by 27 · see citing works

Hallucinations and conscious access to visual inputs in Parkinson’s disease

Lefebvre, S., Baille, G., Jardri, R., Plomhause, L., Szaffarczyk, S., Defebvre, L., Thomas, P., Delmaire, C., Pins, D., & Dujardin, K. (2016) · Scientific Reports · doi:10.1038/srep36284 · Cited by 27 · see citing works

Atrophy of the Cholinergic Basal Forebrain can Detect Presynaptic Cholinergic Loss in Parkinson's Disease

Ray, N. J., Kanel, P., & Bohnen, N. I. (2023) · Annals of Neurology · doi:10.1002/ana.26596 · Cited by 27 · see citing works

Changes in structural network topology correlate with severity of hallucinatory behavior in Parkinson’s disease

Hall, J. M., O’Callaghan, C., Muller, A. J., Martens, K. A. E., Phillips, J. R., Moustafa, A. A., Lewis, S. J. G., & Shine, J. M. (2019) · Network Neuroscience · doi:10.1162/netn_a_00078 · Cited by 25 · see citing works

Prevalence and Risk Factors for Minor Hallucinations in Patients with Parkinson’s Disease

Zhong, M., Gu, R., Zhu, S., Bai, Y., Wu, Z., Jiang, X., Shen, B., Zhu, J., Pan, Y., Yan, J., et al. (2021) · Behavioural Neurology · doi:10.1155/2021/3469706 · Cited by 24 · see citing works

Dependence of connectivity on geometric distance in brain networks

Perinelli, A., Tabarelli, D., Miniussi, C., & Ricci, L. (2019) · Scientific Reports · doi:10.1038/s41598-019-50106-2 · Cited by 23 · see citing works

Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients

Isaacson, S., Ballard, C. G., Kreitzman, D. L., Coate, B., Norton, J. C., Fernandez, H. H., Ilic, T. V., Azulay, J., Ferreira, J. J., Abler, V., et al. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.04.012 · Cited by 23 · see citing works

Drug and Disease Effects in Parkinson's Psychosis: Revisiting the Role of Dopamine

Dave, S., Weintraub, D., Aarsland, D., & Ffytche, D. H. (2019) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12851 · Cited by 21 · see citing works

Clinical Features of Delusional Jealousy in Elderly Patients With Dementia

Hashimoto, M., Sakamoto, S., & Ikeda, M. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09018 · Cited by 20 · see citing works

Ondansetron results in improved auditory gating in DBA/2 mice through a cholinergic mechanism

Wildeboer, K. M., Zheng, L., Choo, K. S., & Stevens, K. E. (2009) · Brain Research · doi:10.1016/j.brainres.2009.08.075 · Cited by 19 · see citing works

Visual hallucinations and inferior longitudinal fasciculus in Parkinson's disease

Yuki, N., Yoshioka, A., Mizuhara, R., et al. (2020) · Brain and Behavior · doi:10.1002/brb3.1883 · Cited by 19 · see citing works

Hallucinations and delusions associated with Parkinson’s disease psychosis: safety of current treatments and future directions

Isaacson, S., & Citrome, L. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2069240 · Cited by 19 · see citing works

A Systematic Review and Case Series of Ziprasidone for Psychosis in Parkinson’s Disease

Younce, J. R., Davis, A. A., & BLACK, K. J. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181448 · Cited by 18 · see citing works

Facilitation of cholinergic transmission by combined treatment of ondansetron with flumazenil after cortical cholinergic deafferentation

Gil-Bea, F. J., Domínguez, J., Garcı́a-Alloza, M., Marcos, B., Lasheras, B., & Ramírez, M. J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.03.014 · Cited by 17 · see citing works

Why psychosis is frequently associated with Parkinson's disease?

Zhong, J., Wu, S., Zhao, Y. H., Chen, H., Zhao, N.-W., Zheng, K.-W., Zhao, Z., Chen, W. K., Wang, B., & Wu, K. (2013) · PubMed Central · doi:10.3969/j.issn.1673-5374.2013.27.006 · Cited by 14 · see citing works

Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.

Clavería, L. E., Teychenne, P. F., Calne, D. B., Petrie, A., & Bassendine, M. F. (1975) · PubMed · Cited by 14 · see citing works

High frequency of psychosis in late-stage Parkinsońs disease

Chendo, I., Fabbri, M., Godinho, C., Simões, R. M., Sousa, C. S. E., Coelho, M. M., Voon, V., & Ferreira, J. J. (2021) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2021.100119 · Cited by 14 · see citing works

Regional Alpha-Synuclein Aggregation, Dopaminergic Dysregulation, and the Development of Drug-Related Visual Hallucinations in Parkinson's Disease

Papapetropoulos, S. (2006) · Journal of Neuropsychiatry · doi:10.1176/jnp.2006.18.2.149 · Cited by 13 · see citing works

Catd: unified representation learning for eeg-to-fmri cross-modal generation

Yao, W., Lyu, Z., Mahmud, M., Zhong, N., Lei, B., & Wang, S. (2025) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2025.3550206 · Cited by 24 · see citing works

Connectome-based brain fingerprints predict early cognitive decline in Parkinson’s patients with minor hallucinations

Stampacchia, S., Bernasconi, F., Van De Ville, D., Amico, E., Pagonabarraga, J., Kulisevsky, J., & Blanke, O. (2025) · doi:10.1101/2025.04.17.649310 · Cited by 5 · see citing works

Deviations in effective connectivity explain different hallucination subtypes in Parkinson's disease psychosis

Vignando, M., Ffytche, D., Mazibuko, N., Palma, G., Bhat, A., Montagnese, M., Dave, S., Tai, Y. F., Batzu, L., Leta, V., et al. (2026) · Nature Mental Health · doi:10.1038/s44220-026-00669-7

Investigation of the behavioral and neurochemical effects of monosodium glutamate on neonatal rats

KARDEŞLER, A. Ç., & Başkale, E. (2017) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1511-92 · Cited by 17 · see citing works

Some Neurochemical Aspects of Convulsions

Lovell, R. A. (1971) · Springer eBooks · doi:10.1007/978-1-4615-7175-9_3 · Cited by 38 · see citing works

Basic Problems in Clinical Application of Microdialysis Technique

Katayama, Y. (1995) · Springer eBooks · doi:10.1007/978-4-431-68522-7_1

Neurochemical findings in the post-mortem schizophrenic brain

Bird, E. D. (1978) · Springer eBooks · doi:10.1007/978-94-011-6206-7_9

Strategies for Study of the Neurochemistry of Attention Deficit Disorder in Children

Hunt, R. D., Cohen, D. J., Shaywitz, S. E., & Shaywitz, B. A. (1982) · Schizophrenia Bulletin · doi:10.1093/schbul/8.2.236 · Cited by 21 · see citing works